Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral semaglutide in type 2 diabetes with cardiovascular disease
NCT03914326Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2019
- Primary completion
- Aug 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 34
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Oral semaglutide with Placebo (2 arms). Primary endpoint: Major Adverse Cardiovascular Event at 265 weeks. Started Jun 2019; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03914326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03914326.